Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $310.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective lifted by Needham & Company LLC from $292.00 to $310.00 in a research note published on Wednesday morning, Marketbeat.com reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday. Robert W. Baird raised their target price on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Stifel Nicolaus set a $275.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Truist Financial set a $264.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Finally, UBS Group reiterated a “buy” rating and set a $315.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $285.44.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $244.54 on Wednesday. The stock has a market cap of $15.88 billion, a price-to-earnings ratio of 16.86, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The stock has a 50 day moving average price of $247.30 and a 200-day moving average price of $218.31. Jazz Pharmaceuticals has a one year low of $123.88 and a one year high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. During the same period in the prior year, the firm posted ($8.25) EPS. The business’s revenue for the quarter was up 15.5% compared to the same quarter last year. Equities analysts expect that Jazz Pharmaceuticals will post 21.51 EPS for the current year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Mark Douglas Smith sold 1,157 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $230.55, for a total value of $266,746.35. Following the transaction, the director owned 9,680 shares of the company’s stock, valued at $2,231,724. This represents a 10.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $252.98, for a total value of $1,517,880.00. Following the completion of the sale, the director owned 360,682 shares in the company, valued at approximately $91,245,332.36. The trade was a 1.64% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 14,357 shares of company stock worth $3,505,642 in the last quarter. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Triumph Capital Management boosted its position in Jazz Pharmaceuticals by 2.0% in the 2nd quarter. Triumph Capital Management now owns 2,597 shares of the specialty pharmaceutical company’s stock valued at $626,000 after buying an additional 52 shares during the period. Cardinal Capital Management increased its position in shares of Jazz Pharmaceuticals by 0.5% during the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock worth $2,471,000 after acquiring an additional 66 shares during the period. Bessemer Group Inc. increased its position in shares of Jazz Pharmaceuticals by 0.3% during the first quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock worth $4,228,000 after acquiring an additional 73 shares during the period. UMB Bank n.a. raised its stake in shares of Jazz Pharmaceuticals by 12.6% during the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock valued at $123,000 after acquiring an additional 81 shares in the last quarter. Finally, Pinnacle Associates Ltd. raised its stake in shares of Jazz Pharmaceuticals by 0.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after acquiring an additional 83 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals News Roundup

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Higher analyst price targets support the bullish case. Truist raised its JAZZ price target to $281, while Needham and other analysts highlighted the potential for further appreciation. The positive views likely reflect Jazz’s earnings power, specialty-pharmaceutical portfolio and recent revenue growth. Truist Financial Boosts Jazz Pharmaceuticals Price Target
• Positive Sentiment: Jazz is pairing its debt issuance with share repurchases. The company priced an upsized $1.1 billion offering of 1.875% exchangeable senior notes due 2032, up from $1 billion, while announcing concurrent ordinary-share buybacks. The low coupon and repurchases could support capital flexibility and per-share results, although exchangeability creates potential future dilution. Jazz Pharmaceuticals Announces Pricing of Exchangeable Senior Notes
• Positive Sentiment: Roche’s expanded FDA approval for a diagnostic linked to a Jazz cancer medicine may broaden patient identification and market access. The development could help physicians identify appropriate patients for the associated therapy, although the commercial benefit to Jazz depends on adoption and the economics of the diagnostic relationship. Roche Receives Expanded FDA Approval for Diagnostic
• Neutral Sentiment: Jazz’s oncology outlook is being reassessed after Ziihera received first-line approval for HER2-positive gastroesophageal cancer. The approval could increase competition in a key oncology setting, but it also underscores the importance of Jazz’s broader oncology pipeline and product positioning. Ziihera First-Line HER2-Positive GEA Approval
• Negative Sentiment: Zacks Research cut several forward EPS estimates. Its FY2026 forecast fell to $20.77 from $21.72, FY2027 to $20.02 from $22.26, and estimates for multiple quarterly periods were also reduced. Although FY2028 EPS was left broadly stable at $22.74, the near- and medium-term downgrades may pressure sentiment and suggest investors are monitoring growth and execution risks.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.